Anand
☆    

India,
2015-07-28 15:47
(3166 d 21:55 ago)

Posting: # 15162
Views: 5,041
 

 Drug Variability ISCV [RSABE / ABEL]

Dear All,

Request to clarify Why drug having highly variable eg like Mesalamine, Prazoles, Statins, Azoles any specific reason?

ISCV due to Structure specific or Functional group or PK Parameter? :confused::confused::confused:

Thanks in Advance.

Regards,
A.Anand
Bio-PK


Edit: Category changed. [Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2015-07-28 16:31
(3166 d 21:12 ago)

@ Anand
Posting: # 15164
Views: 4,273
 

 Science is a cruel mistress

Hi Anand,

❝ Why drug having highly variable […] any specific reason?


A manifold of reasons:
  • Drugs in BCS Class IV (low permeability & solubility) generally show high variability (both within and between subjects). See also the BDDCS (introduced by Wu and Benet)1,2.
  • The high variability may as well be not a property of he drug itself, but of the formulation*. Delayed release pro­ducts are infamous for that. Here it is mainly the physiologic variability in gastric transit which hurts (where mono­lithic formulations ≥ multi­particular ones).
  • High first-pass effect or presystemic metabolization in the gut wall. Enzymes might also get sat­u­rated at higher doses. In such a case variability increases with dose.
  • Excipients may influence trans­porters in the gut wall, gastric motility, in vivo solubilty / stability.
  • And, and, and…
In the context of BE: If high variability is to a larger extent related to the formulation and you are thinking about reference-scaling I would suggest a pilot study in a fully replicated design (RTRT|TRTR or RTR|TRT). If CVwT < CVwR you will get a reward in the required sample size of the pivotal study. Try this in [image]:

library(PowerTOST)
CV <- 0.4
# FDA
sampleN.RSABE(CV=CV, theta0=0.9, design="2x2x4", details=F)
sampleN.RSABE(CV=CVp2CV(CV=CV, ratio=0.67), theta0=0.9, design="2x2x4", details=F)
# EMA
sampleN.scABEL(CV=CV, theta0=0.9, design="2x2x4", details=F)
sampleN.scABEL(CV=CVp2CV(CV=CV, ratio=0.67), theta0=0.9, design="2x2x4", details=F)



  1. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and develop­ment of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. doi:10.1007/s11095-004-9004-4.
  2. Benet LZ, Broccatelli F, Oprea TI. BDDCS Applied to Over 900 Drugs. AAPS J. 2011;13(4):519–47. doi:10.1208/s12248-011-9290-9. [image] free resource

  • Hence, the distinction between HVDs (Highly Variable Drugs) and HVDPs (Highly Variable Drug Pro­ducts). The former show high variability already if administered as a solution.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
104 visitors (0 registered, 104 guests [including 9 identified bots]).
Forum time: 12:43 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5